Reactogenicity, Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Investigational Supra-seasonal Universal Influenza Vaccines - Inactivated (SUIVs) (GSK3816302A) in Healthy Adults
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 15 Mar 2018
At a glance
- Drugs Supra-seasonal-universal-influenza-vaccine-inactivated-GlaxoSmithKline (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions; First in man; Pharmacodynamics
- Acronyms FLU D-SUIV-ADJ-001
- Sponsors GlaxoSmithKline
- 12 Mar 2018 Status changed from recruiting to active, no longer recruiting.
- 08 Mar 2018 Planned End Date changed from 20 Apr 2020 to 7 May 2020.
- 08 Mar 2018 Planned primary completion date changed from 20 Apr 2020 to 7 May 2020.